Emergency Contraception Global Market Report 2026

The emergency contraception market size has grown strongly in recent years. It will grow from $1.55 billion in 2025 to $1.66 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increasing awareness of emergency contraception, rising contraceptive failure rates, expansion of retail pharmacy networks, growing demand for hormonal contraceptives, regulatory approvals for emergency contraceptive pills.

The emergency contraception market size is expected to see strong growth in the next few years. It will grow to $2.16 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to increasing adoption of online pharmacy platforms, growing demand for homecare delivery services, expansion of age-specific awareness programs, rising preference for non-hormonal and herbal alternatives, introduction of high-dose and multi-formulation products. Major trends in the forecast period include increasing availability of over-the-counter emergency contraceptives, rising adoption of online pharmacies and home delivery services, growing focus on adolescent and adult awareness programs, expansion of high-dose and multi-formulation options, rising integration of copper intrauterine devices and non-hormonal methods.

The increasing rates of unprotected intercourse are expected to drive the growth of the emergency contraception market going forward. Unprotected intercourse refers to sexual activity conducted without using any form of barrier contraception, such as condoms, or other effective birth control methods, leaving participants susceptible to unintended pregnancies and sexually transmitted infections. The incidence of unprotected intercourse is rising due to declining condom use and inconsistent adoption of other contraceptive methods among sexually active individuals, particularly young adults and adolescents, which increases the likelihood of unprotected sexual encounters. Emergency contraception serves as an important safety measure following unprotected intercourse by preventing unintended pregnancies, thereby directly addressing the consequences of missed or no contraception and reducing immediate risks associated with unprotected sexual activity. For instance, according to the 2023 National Youth Risk Behavior Survey by the Centers for Disease Control and Prevention, a US-based government agency, in a 2023 survey of U.S. high school students, 32% reported having had sexual intercourse at least once, and 48% indicated they did not use a condom during their most recent sexual encounter. Therefore, the rising rates of unprotected intercourse are propelling the growth of the emergency contraception market.

Key companies operating in the emergency contraception market are focusing on developing innovative products such as over-the-counter emergency contraceptives to increase accessibility and provide rapid, effective pregnancy prevention. Over-the-counter emergency contraceptives are oral pills containing hormones such as levonorgestrel that can be purchased without a prescription and help prevent pregnancy by delaying ovulation or fertilization when taken shortly after unprotected sex. For example, in August 2024, Verséa Health Inc., a US-based healthcare company specializing in diagnostics and consumer health solutions, launched Empowered Choice, a U.S. Food and Drug Administration-approved over-the-counter emergency contraceptive aimed at expanding accessible options in mainstream retail and online channels. The launch included nationwide distribution partnerships with major pharmacies and e-commerce platforms, combined with a comprehensive educational campaign to raise awareness about emergency contraception options, proper usage, and timing for optimal effectiveness. The initiative sought to reach a wider audience, reduce stigma around emergency contraception, and ensure that individuals could obtain the product quickly and discreetly. The product features a simple oral levonorgestrel formulation that ensures effective emergency pregnancy prevention, can be used without a prescription, and provides individuals with increased autonomy and flexibility in reproductive health decision-making.

In March 2023, Curae Pharma360 Inc., a US-based pharmaceutical company specializing in over-the-counter (OTC) emergency contraceptives, partnered with Direct Relief to provide OTC emergency contraception to underserved women. Through this collaboration, Curae Pharma360 Inc. and Direct Relief aim to enhance equitable access to essential medicines, deliver timely reproductive healthcare solutions, and support community health initiatives for women in need. Direct Relief is a US-based nonprofit organization offering medical assistance and disaster relief to improve health outcomes.

Major companies operating in the emergency contraception market are Pfizer Inc.; Bayer Aktiengesellschaft, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Cipla Limited, Amneal Pharmaceuticals Inc., Lupin Limited, Gedeon Richter Plc, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Mankind Pharma Limited, Piramal Pharma Limited, CooperSurgical Inc., HLL Lifecare Limited, Zhejiang Xianju Pharmaceutical Co. Ltd., AdvaCare Pharma, Afaxys Inc., Syzygy Healthcare Solutions, Foundation Consumer Healthcare, Shanghai Dahua Pharmaceutical Co. Ltd.

North America was the largest region in the emergency contraception market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the emergency contraception market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the emergency contraception market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The emergency contraception market consists of sales of combined hormonal emergency contraceptive pills, copper intrauterine devices (IUDs), over-the-counter emergency contraceptive products, and emergency contraceptive pill kits. Values in this market are “factory gate” values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services such as regulatory compliance support, packaging, labeling, and pharmacovigilance services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Emergency contraception is a method employed to prevent pregnancy following unprotected sexual intercourse or contraceptive failure. It usually involves high-dose hormonal pills or the placement of a copper intrauterine device. Its effectiveness is greatest when used as soon as possible after the event, ideally within 72 hours.

The key product types of emergency contraception include levonorgestrel, ulipristal acetate, mifepristone, and other variants. Levonorgestrel is a hormonal formulation used to prevent pregnancy after unprotected intercourse or contraceptive failure. Dosage forms include tablets, injections, and others, administered to adolescents and adults. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others, serving hospitals, clinics, homecare, and other end users.

Tariffs on imported hormonal pills, copper IUD components, and raw materials are impacting the emergency contraception market by increasing costs for manufacturers and distributors, particularly affecting levonorgestrel, ulipristal acetate, and mifepristone products. Regions such as North America, Europe, and Asia-Pacific that rely on imported pharmaceuticals and device components are most affected. While tariffs increase procurement costs, they also encourage local production, promote domestic manufacturing of contraceptive products, and foster innovation in affordable and diversified formulations, benefiting regional supply chains.

The emergency contraception market research report is one of a series of new reports that provides emergency contraception market statistics, including emergency contraception industry global market size, regional shares, competitors with a emergency contraception market share, detailed emergency contraception market segments, market trends and opportunities, and any further data you may need to thrive in the emergency contraception industry. This emergency contraception market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.